{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:05:06Z","timestamp":1784909106752,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2019-000606","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T05:19:26Z","timestamp":1574831966000},"page":"e000606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-5479","authenticated-orcid":false,"given":"Kyriaki","family":"Tzogani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meulendijks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Herberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Hennik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Verheijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torunn","family":"Wangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro","family":"Dahlseng H\u00e5konsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torny","family":"Kaasboll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Dalhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorg","family":"Bolstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Salmonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pignatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000606_bb0010","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1002\/cncr.25908","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?","volume":"117","author":"Pemmaraju","year":"2011","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2019-000606_bb0015","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0025","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0030","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0035","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/1042819031000151851","article-title":"Internal tandem duplications of Flt3 gene (Flt3\/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia","volume":"45","author":"Ciolli","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1136\/esmoopen-2019-000606_bb0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1136\/esmoopen-2019-000606_bb0050","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0055","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0060","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0065","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1136\/esmoopen-2019-000606_bb0070","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000606_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0080","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000606_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.thj.6200165","article-title":"A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C","volume":"3","author":"Virchis","year":"2002","journal-title":"Hematol J"},{"key":"10.1136\/esmoopen-2019-000606_bb0090","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1136\/esmoopen-2019-000606_bb0095","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0100","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000606_bb0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1136\/esmoopen-2019-000606_bb0110","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0120","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1136\/esmoopen-2019-000606_bb0125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:47Z","timestamp":1761855767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"alternative-id":["S2059702920300971"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000606","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000606"}}